Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Assets Average (2019 - 2025)

BioNexus Gene Lab's Assets Average history spans 7 years, with the latest figure at $8.5 million for Q3 2025.

  • For Q3 2025, Assets Average fell 23.01% year-over-year to $8.5 million; the TTM value through Sep 2025 reached $8.5 million, down 23.01%, while the annual FY2024 figure was $10.9 million, 8.41% up from the prior year.
  • Assets Average for Q3 2025 was $8.5 million at BioNexus Gene Lab, down from $9.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $11.4 million in Q4 2023 and bottomed at $8.0 million in Q2 2023.
  • The 5-year median for Assets Average is $9.7 million (2021), against an average of $9.6 million.
  • The largest annual shift saw Assets Average surged 826.62% in 2021 before it decreased 23.01% in 2025.
  • A 5-year view of Assets Average shows it stood at $9.7 million in 2021, then decreased by 14.48% to $8.3 million in 2022, then surged by 38.26% to $11.4 million in 2023, then decreased by 6.28% to $10.7 million in 2024, then dropped by 20.47% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Assets Average are $8.5 million (Q3 2025), $9.5 million (Q2 2025), and $10.0 million (Q1 2025).